PKM and adenocarcinoma: However, Rzechonek et al. (2017) suggested that PKM2 might not be an ideal diagnostic and prognostic biomarker in NSCLC because the specificity of PKM2 as a cancer marker was 50% for both adenocarcinoma and squamous cell carcinoma.